



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Gonadotropin Releasing Hormone Agonist

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Form with fields for Patient Name, HPP Member Number, Date of Birth, Address, City, State ZIP, Patient Primary Phone, Line of Business (Medicaid, CHIP), Prescriber Name, Fax, Phone, Office Contact, NPI, Promise ID, Prescriber PA PROMISe ID, Address, City, State ZIP, Specialty/facility name (if applicable).

Expedited/Urgent checkbox

Drug Name:

Strength:

Days Supply:

Number of Refills:

Directions / SIG:

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this request for the treatment of gender dysphoria? (If so, please refer to the Treatment of Gender Dysphoria criteria).

Yes checkbox

No checkbox

Q2. Is the request for a formulary medication?

Yes checkbox

No checkbox

Q3. Has the patient tried and failed or has a contraindication or intolerance to formulary medications? (Please attach documentation).

Yes checkbox

No checkbox

Q4. What is the drug being requested for?

checkbox

For the Management of Endometriosis

checkbox

For the Preoperative Hematologic Improvement of Patients with Anemia Caused by Uterine Leiomyomata

checkbox

For Palliative Treatment of Advanced Prostate Cancer

checkbox

For the Treatment of Children with Central Precocious Puberty

Q5. Does the patient have a diagnosis of endometriosis confirmed by a workup/evaluation (versus presumptive treatment)? (Please attach documentation).

Yes checkbox

No checkbox

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Gonadotropin Releasing Hormone Agonist

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

Q6. Is the medication being requested for management of endometriosis, including pain relief and reduction of endometriotic lesions?

Yes

No

Q7. Is the patient 18 years of age or older?

Yes

No

Q8. Is the patient pregnant?

Yes

No

Q9. Is the request from, or in consultation with, a gynecologist?

Yes

No

Q10. If requesting Lupron Depot, is it being prescribed as combination treatment with norethindrone 5 mg once daily? (When combination treatment is not going to be prescribed, please attach documentation as to the reason why the risks of Lupron Depot in combination treatment with norethindrone outweigh the benefits).

Yes

No

Q11. Has the patient experienced trial and failure and/or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs) AND at least one 3 month course of a contraceptive (either oral or non-oral) or depot medroxyprogesterone acetate?

Yes

No

Q12. Does the patient have a diagnosis of uterine leiomyomata confirmed by a workup/evaluation (versus presumptive treatment)? (Please attach documentation).

Yes

No

Q13. Is Lupron Depot being requested for preoperative hematologic improvement of a patient with anemia caused by uterine leiomyomata? (Please attach documentation).

Yes

No

Q14. Is the patient 18 years of age or older?

Yes

No

Q15. Is the patient pregnant?

Yes

No

Q16. Is the request from, or in consultation with, a gynecologist?

Yes

No

Q17. Does the patient have anemia that did not respond to treatment with a one month trial of iron alone?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Gonadotropin Releasing Hormone Agonist

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

Yes

No

Q18. Has the patient experienced trial and failure and/or intolerance to at least one 3 month course of treatment with a contraceptive (either oral or non-oral)?

Yes

No

Q19. Is Lupron Depot to be used concomitantly with iron?

Yes

No

Q20. Does the patient have a histologically confirmed diagnosis of advanced prostate cancer? (Please attach documentation).

Yes

No

Q21. Is the patient 18 years of age or older?

Yes

No

Q22. Is the request from, or in consultation with, an oncologist or urologist?

Yes

No

Q23. Will serum testosterone and PSA levels be periodically monitored throughout the course of treatment?

Yes

No

Q24. Does the patient have a diagnosis of central precocious puberty? (Please attach documentation).

Yes

No

Q25. Is the patient less than 11 years of age if a female or less than 12 years of age if a male?

Yes

No

Q26. Did the onset of secondary sexual characteristics begin before the age of 8 if a female OR before the age of 9 if a male?

Yes

No

Q27. Has the diagnosis been confirmed by a response to a GNRH stimulation test, or if not available, other labs to support the diagnosis of Central Precocious Puberty (such as luteinizing hormone levels, estradiol, testosterone level)? (Please attach documentation).

Yes

No

Q28. Have baseline evaluations including height, weight, and the following been completed? (Please attach documentation).

- a. Diagnostic imaging of the brain to rule out intracranial tumor
- b. Pelvic/testicular/adrenal ultrasound to rule out steroid secreting tumors
- c. Human chorionic gonadotropin levels to rule out a chorionic gonadotropin secreting tumor (males only)

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Gonadotropin Releasing Hormone Agonist

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

d. Adrenal steroid measurements to exclude congenital adrenal hyperplasia

Yes

No

Q29. Requested Duration:

3 Months

6 Months

Q30. Additional Information:

Prescriber Signature

Date

Updated 2018